Leishmaniasis worldwide and global estimates of its incidence, PLoS One, vol.7, 2012. ,
Old World cutaneous leishmaniasis: diagnosis and treatment, J Dermatol Case Rep, vol.7, pp.31-41, 2013. ,
The cure rate after placebo or no therapy in American cutaneous leishmaniasis: a systematic review and meta-analysis, PLoS One, vol.11, pp.1-15, 2016. ,
New World and Old World leishmania infections: a practical review, Dermatol Clin, vol.33, pp.579-593, 2015. ,
Therapeutic modalities to combat leishmaniasis, a review, Asian Pacific J Trop Dis, vol.6, pp.60975-60981, 2016. ,
An update on pharmacotherapy for leishmaniasis, Expert Opin Pharmacother, vol.2, pp.237-252, 2015. ,
Is paromomycin an effective and safe treatment against cutaneous leishmaniasis? A metaanalysis of 14 randomized controlled trials, PLoS Negl Trop Dis, vol.3, 2009. ,
Fasl and TRAIL signaling in the skin during cutaneous leishmaniasis: implications for tissue immunopathology and infectious control, Front Immunol, vol.3, pp.1-8, 2012. ,
The 500 Dalton rule for the skin penetration of chemical compounds and drugs, Exp Dermatol, vol.9, pp.165-169, 2000. ,
Penetration enhancers, Adv Drug Deliv Rev, vol.64, pp.128-137, 2012. ,
Short report: Intralesional meglumine antimoniate for treatment of cutaneous leishmaniasis patients with contraindication to systemic therapy from Rio de Janeiro, Am J Trop Med Hyg, vol.87, pp.257-260, 2000. ,
Efficacy of intralesional amphotericin B for the treatment of cutaneous leishmaniasis, Indian J Dermatol, vol.59, pp.631-636, 2014. ,
Adverse effects of intralesional meglumine antimoniate and its influence on clinical laboratory parameters in the treatment of cutaneous leishmaniasis, Int J Dermatol, vol.51, pp.1221-1225, 2012. ,
Clinical response with intralesional amphotericin B in the treatment of Old World cutaneous leishmaniasis: a preliminary report, Dermatol Ther, vol.29, pp.398-405, 2016. ,
Manual de vigilância da leishmaniose tegumentar recurso eletrônico. Ministério da Saúde, Secretaria de Vigilância em Saúde, Departamento de Vigilância das Doenças Transmissívei, Sao Paolo, 2017. ,
FDA's regulatory science program for generic PLA/PLGA-based drug products, Am Pharm Rev, vol.19, pp.5-9, 2016. ,
Review article: fabricated microparticles: an innovative method to minimize the side effects of NSAIDs in arthritis, Crit Rev Ther Drug Carrier Syst, vol.33, pp.433-488, 2016. ,
Gliadel® wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial, Acta Neurochir, vol.148, pp.269-275, 2006. ,
Leuprolide acetate depot and hormonal add-back in endometriosis: a 12-month study. Lupron Add-Back Study Group, Obstet Gynecol, vol.91, pp.16-24, 1998. ,
Risperidone long-acting injectable (Risperdal Consta®) for maintenance treatment in patients with bipolar disorder, Expert Rev Neurother, vol.10, pp.1637-1658, 2010. ,
Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier, Polymers (Basel), vol.3, pp.1377-1397, 2011. ,
The chemotherapeutic potential of chalcones against leishmaniases: a review, Int J Antimicrob Agents, vol.2017, pp.1-28, 2017. ,
New administration model of trans-chalcone biodegradable polymers for the treatment of experimental leishmaniasis, Acta Trop, vol.98, pp.59-65, 2006. ,
Improvement of in vitro and in vivo antileishmanial activities of 2=,6=-dihydroxy-4=-methoxychalcone by entrapment in poly(D,L-lactide) nanoparticles, Antimicrob Agents Chemother, vol.43, pp.1776-1778, 1999. ,
Synthesis of chalcone analogues with increased antileishmanial activity, Bioorganic Med Chem, vol.14, pp.1538-1545, 2006. ,
Suppression of LPS-induced inflammatory responses in macrophages infected with leishmania, J Inflamm, vol.7, 2010. ,
Subversion mechanisms by which leishmania parasites can escape the host immune response: a signaling point of view, Clin Microbiol Rev, vol.18, pp.293-305, 2005. ,
Leishmania amazonensisinduced inhibition of nitric oxide synthesis in host macrophages, vol.4, pp.23-29, 2002. ,
A review of anti-infective and anti-inflammatory chalcones, Eur J Med Chem, vol.42, pp.125-137, 2007. ,
Selective effect of 2=,6=-dihydroxy-4=-methoxychalcone isolated from Piper aduncum on Leishmania amazonensis, Antimicrob Agents Chemother, vol.43, pp.1234-1241, 1999. ,
PLA micro-and nanoparticles, Adv Drug Deliv Rev, vol.107, pp.176-191, 2016. ,
Poly-lactic-co-glycolic acid (PLGA) copolymer and its pharmaceutical application, Handbook of polymers for pharmaceutical technologies, pp.151-172, 2016. ,
Doublewalled microspheres loaded with meglumine antimoniate: preparation, characterization, and in vitro release study, Drug Dev Ind Pharm, vol.40, pp.701-710, 2014. ,
Development of liposomes loaded with antileishmanial drugs for the treatment of cutaneous leishmaniasis, J Liposome Res, vol.23, pp.134-144, 2013. ,
Role of particle size in phagocytosis of polymeric microspheres, Pharm Res, vol.25, pp.1815-1821, 2008. ,
Nanoparticles for drug delivery: the need for precision in reporting particle size parameters, Eur J Pharm Biopharm, vol.69, pp.1-9, 2008. ,
The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles, Int J Nanomed, vol.7, pp.5577-5591, 2012. ,
The uptake of PLGA microor nanoparticles by macrophages provokes distinct in vitro inflammatory response, Int Immunopharmacol, vol.11, pp.1557-1563, 2011. ,
Synthesis, antioxidant evaluation, and quantitative structure-activity relationship studies of chalcones, Med Chem Res, vol.20, pp.482-492, 2011. ,
Novel anti-inflammatory chalcone derivatives inhibit the induction of nitric oxide synthase and cyclooxygenase-2 in mouse peritoneal macrophages, FEBS Lett, vol.453, pp.707-710, 1999. ,
In vitro phagocytosis and monocyte-macrophage activation with poly(lactide) and poly(lactide-co-glycolide) microspheres, Eur J Pharm Sci, vol.15, pp.197-207, 2002. ,
Antimony in plasma and skin of patients with cutaneous leishmaniasis: relationship with side effects after treatment with meglumine antimoniate, Trop Med Int Heal, vol.14, pp.1515-1522, 2009. ,
, Guide for the care and use of laboratory animals, National Academy of Sciences, 2011.
Enzymes of carbohydrate metabolism in four human species of leishmania: a comparative survey, J Protozool, vol.23, pp.600-607, 1976. ,
Nitric oxide: a physiologic messenger molecule, Annu Rev Biochem, vol.63, pp.175-195, 1994. ,
A simple method for quantifying leishmania in tissues of infected animals, Parasitol Today, vol.13, pp.80-82, 1997. ,
Effectiveness of the local or oral delivery of the novel naphthopterocarpanquinone LQB-118 against cutaneous leishmaniasis, J Antimicrob Chemother, vol.66, pp.1555-1559, 2011. ,
CCl 4 -induced acute liver injury in mice is inhibited by hepatocyte growth factor overexpression but stimulated by NK2 overexpression, FEBS Lett, vol.532, pp.3714-3720, 2002. ,
, Single-Dose Treatment for Cutaneous Leishmaniasis Antimicrobial Agents and Chemotherapy